Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (GB:0REN)
LSE:0REN
RESEARCH TOOLSreports
Edwards Lifesciences (0REN) Share Price & Analysis
0 Followers
0REN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Edwards Lifesciences News
Bulls Say, Bears Say
Bulls Say
Financial Guidance And PerformanceManagement's increased confidence in achieving the upper end of the full-year revenue guidance underscores the company's strong financial performance and growth prospects.
Market Share And Growth StrategyThe S3UR launch aims to regain market share in Europe, coupled with improved growth in Japan, highlighting strategic moves to bolster the company's market position.
Product Launch And Market OpportunityThe successful launch of the Evoque TTVR system, as the first commercially available transcatheter tricuspid valve platform in the US, taps into a significant market opportunity potentially exceeding $1B.
Bears Say
Financial PerformanceHigher than expected SG&A drove a ~180bp operating margin miss, which may be viewed critically by some investors.
Product PerformanceSmart trial reported a 20% paravalvular leak rate for Sapien 3, which is higher than the 10-12% rates observed in real-world registries such as the TVT registry.
Regulatory ChallengesBSX no longer expects FDA approval in 2024; management suspended enrollment in the single arm continued access study.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.06% Insiders
22.84% Mutual Funds
24.81% Other Institutional Investors
51.29% Public Companies and
Individual Investors
0REN FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Currently, no data Available
What is Edwards Lifesciences’s market cap?
Currently, no data Available
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Jul 25, 2024 which is in 81 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 25, 2024. The company reported CHF0.605 earnings per share for the quarter, beating the consensus estimate of CHF0.59 by CHF0.016.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is CHF0.64.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 602,600,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of CHF0.605 in its last earnings report, beating expectations of CHF0.59. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Among the largest hedge funds holding Edwards Lifesciences’s share is Fisher Asset Management LLC. It holds Edwards Lifesciences’s shares valued at 544M.
---
Edwards Lifesciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF87.09 (― Upside)
CHF87.09 (― Upside)
Blogger Sentiment
Bullish
GB:0REN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $6.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.23%
12-Months-Change
Fundamentals
Return on Equity
21.59%
Trailing 12-Months
Asset Growth
12.54%
Trailing 12-Months
Company Description
Edwards Lifesciences
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
0REN Earnings Call
Q1 2024
0:00 / 0:00
---
0REN Net sales Breakdown
64.61% Transcatheter Aortic Valve Replacement
16.64% Surgical Structural Heart
15.46% Critical Care
3.29% Transcatheter Mitral and Tricuspid Therapies
---
0REN Stock 12 Months Forecast
Average Price Target
―Edwards Lifesciences
―
Medtronic
―
Integra Lifesciences
―
Becton Dickinson
―
Boston Scientific
―
Best Analysts Covering 0REN
1 Year
1 Year Success Rate
23/32 ratings generated profit
1 Year Average Return
+18.92%
reiterated a buy rating 24 days ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 71.88% of your transactions generating a profit, with an average return of +18.92% per trade.
---